On June 9, 2017 Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, reported significant progress with yet another Patent Cooperation Treaty (PCT) patent application within its intellectual property (IP) portfolio (Press release, Propanc, JUN 9, 2017, View Source [SID1234519486]). Schedule your 30 min Free 1stOncology Demo! The Company received a Written Opinion from an International Search Authority regarding the novelty, inventive step and industrial applicability of the invention claimed in the recent PCT application, filed in April, 2017. The PCT application titled "Composition of Proenzymes for Cancer Treatment" is directed to a composition comprising trypsinogen and chymotrypsinogen, targeting specific weight ratios and certain dosage levels for the Company’s lead product, PRP. The majority of claims were considered novel and a number of claims considered inventive, as determined by the Authorized Officer from the Australian Patent Office. Furthermore, it appears that the experimental data included in the application and the way it is presented adequately supports the pending claims. The PCT assists applicants in seeking patent protection internationally for their inventions and the Written Opinion can guide national patent offices with their patent granting decisions. By filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in over 150 countries.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We continue to make significant progress with our IP portfolio and look forward to entering the national phase where we will seek to obtain jurisdiction in key countries and regions, globally," said James Nathanielsz, Propanc Biopharma’s Chief Executive Officer. "We remain committed to further establishing ourselves as the lead player in a new and exciting field of oncology, using proenzymes as a means to halt progression of cancer from solid tumors. Hence, we continue to work hard along with our partner research organizations and scientific experts to explore new opportunities to expand our portfolio, and to also discover new treatments methods and compounds which even further enhances the effects of PRP."
The Company’s lead product, PRP, is a solution for once daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen. Currently progressing towards First-In-Human studies, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 Billion by 2020. The Company’s initial target patient populations are pancreatic, ovarian and colorectal cancers, representing a combined market segment of $14 Billion predicted in 2020, by GBI Research.
To view Propanc Biopharma’s "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: View Source
To be added to Propanc Biopharma’s email distribution list, please click on the following link: View Source and submit the online request form.